The insulin market is expected to grow by 15% by 2020.

The government's initiative aims to increase the affordability of insulin through price reductions, such as cooperation between the governments of Ukraine and the United States, and is expected to reduce insulin prices by 20% by 2013, with a positive impact on demand.
Other drivers of the market include an increasing number of attempts by manufacturers to leverage open new manufacturing units to improve the supply of insulin and increase the incidence of type II diabetes as a factor in some expected future fuel market growth.
From a regional perspective, Russia occupied the largest share of the market, accounting for 69.2% of revenue. Its large share is provided by the Russian government with a more substantial subsidy for insulin patients.
Ukraine is expected to register the fastest compound annual growth rate of 15.6 per cent for the projected period, owing to high untapped opportunities and encouraging the existence of government measures.
In addition, Poland is expected to grow in a profitable period, mainly due to high diabetes prevalence and increased health care spending.